ICUdata4EU General Assembly 2026: A Federated Platform Advances Towards Implementation and Clinical Validation

On 10 and 11 September 2026, the ICUdata4EU consortium met at FORTH (Foundation for Research and Technology) in Crete, Greece. The hybrid General Assembly brought together partners from across Europe to review project progress and define priorities for the next phase.

A key milestone was the live demonstration of the operational ICUdata platform. The end-to-end scenario showed how a research project can be initiated within a governed environment: a data user invites a hospital to participate, the required organisational and data-sharing checks are applied, and a cohort can be configured. The platform can then return a patient count from a hospital satellite node, while access remains policy-controlled and the hospital retains authority over its participation and the data it makes available.

The consortium also reviewed progress towards clinical validation. Four use cases were confirmed, covering acute kidney injury, haemodynamic instability, coagulation, and metabolic instability. The acute kidney injury use case is ready to move into validation. Together, these use cases will help demonstrate how routinely collected laboratory and vital-sign data can support standardised cohort identification across different clinical settings.

Deployment is progressing across the hospital network. Nine hospitals in five countries are currently involved, and partners discussed how to extend participation to additional sites and countries. Local preparation remains essential: each hospital must address its own ethics, legal, data-protection, IT, and cybersecurity requirements before clinical data can be accessed. The consortium will support this work with implementation guidance and shared templates.

Looking beyond the project’s funded period, partners discussed how the ICUdata Hub could continue to operate in a sustainable way. The discussion focused on a possible public-interest, cost-recovery model, with voluntary participation and any future payments linked to services rather than the sale of health data. Further work will define governance, services, legal implications, and partner obligations.

The General Assembly therefore marked a practical step forward: the platform is operational, clinical use cases are advancing towards validation, and the consortium is preparing to expand deployment while developing a sustainable basis for European collaboration.